Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 15

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 15
---
) Exhibits

The following exhibits are being filed herewith:

| Exhibit No. 
 3.1†        
 10.1*†      |     | Document                                                                                                                                                                                                                                                                                 
 Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock, dated October 14, 2025.                                                                                                                                                   
 Securities Purchase Agreement, dated as of October 14, 2025, by and between CERo Therapeutics Holdings, Inc. and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No. 001-40877) filed on October 14, 2025). |
|:------------|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104         |     | Cover Page Interactive Data File (embedded within the Inline XBRL document).                                                                                                                                                                                                             |

| * | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |

| † | Certain portions of this document that constitute confidential information have been redacted pursuant to Item 601(b)(10) of Regulation S-K. |

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Dated: October 16, 2025 | CERO THERAPEUTICS HOLDINGS, INC. |                         |
|:------------------------|:---------------------------------|:------------------------|
|                         | By:                              | /s/ Chris Ehrlich       |
|                         | Name:                            | Chris Ehrlich           |
|                         | Title:                           | Chief Executive Officer |

<div align='center'>2</div>